Literature DB >> 28523586

Ocrelizumab: First Global Approval.

James E Frampton1.   

Abstract

Ocrelizumab (Ocrevus™) is a humanised anti-CD20 monoclonal antibody that has been developed by Genentech, Inc. (a subsidiary of Roche) for the treatment of multiple sclerosis (MS). The drug is designed to deplete B cells, which play an important role in the pathogenesis of MS. In March 2017, ocrelizumab was approved in the USA for the treatment of patients with relapsing or primary progressive forms of MS; currently, it is awaiting approval in the EU for the same indications. This article summarizes the milestones in the development of ocrelizumab leading to its first global approval for the treatment of MS.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28523586     DOI： 10.1007/s40265-017-0757-6

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   11.431


  7 in total

1.  Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Authors:  Stephen L Hauser; Amit Bar-Or; Giancarlo Comi; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Xavier Montalban; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Jerry S Wolinsky; Douglas L Arnold; Gaelle Klingelschmitt; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Peter Chin; Nicole Mairon; Hideki Garren; Ludwig Kappos
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

2.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Authors:  Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

Review 3.  The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects.

Authors:  Per Soelberg Sorensen; Morten Blinkenberg
Journal:  Ther Adv Neurol Disord       Date:  2016-01       Impact factor: 6.570

4.  Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

Authors:  Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik Barkhof; Ming Yin; David Leppert; Robert Glanzman; Jeroen Tinbergen; Stephen L Hauser
Journal:  Lancet       Date:  2011-10-31       Impact factor: 79.321

5.  Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study.

Authors:  Eduardo F Mysler; Alberto J Spindler; Renato Guzman; Marc Bijl; David Jayne; Richard A Furie; Frédéric A Houssiau; Jorn Drappa; David Close; Romeo Maciuca; Kajal Rao; Saba Shahdad; Paul Brunetta
Journal:  Arthritis Rheum       Date:  2013-09

6.  Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma.

Authors:  F Morschhauser; P Marlton; U Vitolo; O Lindén; J F Seymour; M Crump; B Coiffier; R Foà; E Wassner; H-U Burger; B Brennan; M Mendila
Journal:  Ann Oncol       Date:  2010-02-15       Impact factor: 32.976

7.  Safety with ocrelizumab in rheumatoid arthritis: results from the ocrelizumab phase III program.

Authors:  Paul Emery; William Rigby; Paul P Tak; Thomas Dörner; Ewa Olech; Carmen Martin; Laurie Millar; Helen Travers; Elena Fisheleva
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240
  7 in total
  6 in total

Review 1.  Promoting remyelination through cell transplantation therapies in a model of viral-induced neurodegenerative disease.

Authors:  Vrushali Mangale; Laura L McIntyre; Craig M Walsh; Jeanne F Loring; Thomas E Lane
Journal:  Dev Dyn       Date:  2018-09-06       Impact factor: 3.780

2.  Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies.

Authors:  Anat Achiron; Mathilda Mandel; Sapir Dreyer-Alster; Gil Harari; David Magalashvili; Polina Sonis; Mark Dolev; Shay Menascu; Shlomo Flechter; Rina Falb; Michael Gurevich
Journal:  Ther Adv Neurol Disord       Date:  2021-04-22       Impact factor: 6.570

3.  Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.

Authors:  Carla Tortorella; Alessandra Aiello; Claudio Gasperini; Chiara Agrati; Concetta Castilletti; Serena Ruggieri; Silvia Meschi; Giulia Matusali; Francesca Colavita; Chiara Farroni; Gilda Cuzzi; Eleonora Cimini; Eleonora Tartaglia; Valentina Vanini; Luca Prosperini; Shalom Haggiag; Simona Galgani; Maria Esmeralda Quartuccio; Andrea Salmi; Federica Repele; Anna Maria Gerarda Altera; Flavia Cristofanelli; Alessandra D'Abramo; Nazario Bevilacqua; Angela Corpolongo; Vincenzo Puro; Francesco Vaia; Maria Rosaria Capobianchi; Giuseppe Ippolito; Emanuele Nicastri; Delia Goletti
Journal:  Neurology       Date:  2021-11-22       Impact factor: 11.800

Review 4.  Bruton's Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?

Authors:  Anastasia Geladaris; Sebastian Torke; Martin S Weber
Journal:  CNS Drugs       Date:  2022-09-30       Impact factor: 6.497

5.  Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders.

Authors:  Andrea Marcinnò; Fabiana Marnetto; Paola Valentino; Serena Martire; Alessia Balbo; Aurora Drago; Maria Leto; Marco Capobianco; Giancarlo Panzica; Antonio Bertolotto
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2018-09-13

Review 6.  A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.

Authors:  Esther S Frisch; Roxanne Pretzsch; Martin S Weber
Journal:  Neurotherapeutics       Date:  2021-04-20       Impact factor: 7.620
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.